PDT Partners’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-75,318
Closed -$1.09M 544
2026
Q1
$1.09M Sell
75,318
-374,681
-83% -$5.37M 0.06% 322
2025
Q4
$6.41M Sell
449,999
-56,053
-11% -$551K 0.42% 60
2025
Q3
$3.99M Hold
506,052
0.25% 141
2025
Q2
$2.9M Sell
506,052
-235,263
-32% -$1.52M 0.16% 216
2025
Q1
$6.05M Buy
741,315
+388,817
+110% +$3.6M 0.43% 40
2024
Q4
$3.32M Buy
352,498
+99,539
+39% +$1.03M 0.29% 112
2024
Q3
$2.7M Buy
+252,959
New +$2.75M 0.24% 140
2022
Q4
Sell
-30,505
Closed -$318K 723
2022
Q3
$318K Buy
+30,505
New +$340K 0.05% 566
2022
Q2
Sell
-32,921
Closed -$312K 1021
2022
Q1
$312K Buy
+32,921
New +$309K 0.03% 713
2019
Q3
Sell
-316,400
Closed -$3.95M 465
2019
Q2
$3.95M Hold
316,400
0.23% 129
2019
Q1
$4.3M Sell
316,400
-22,000
-7% -$269K 0.24% 125
2018
Q4
$3.24M Buy
338,400
+245,816
+266% +$2.7M 0.18% 155
2018
Q3
$1.12M Buy
+92,584
New +$1.29M 0.05% 301
2015
Q3
Sell
-227,026
Closed -$3.21M 1365
2015
Q2
$3.21M Buy
227,026
+92,357
+69% +$1.11M 0.08% 293
2015
Q1
$1.47M Buy
134,669
+35,402
+36% +$312K 0.04% 580
2014
Q4
$826K Sell
99,267
-14,033
-12% -$96.3K 0.08% 374
2014
Q3
$674K Buy
+113,300
New +$594K 0.02% 844

Other funds holding FOLD

PDT Partners's FOLD Position: Q2 2026 in Review

PDT Partners sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 75,318 shares — an estimated $1.09M sold.

PDT Partners first reported a position in FOLD in Q3 2014 and held it in 17 quarters. The position peaked at $6.41M in Q4 2025. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • PDT Partners reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • PDT Partners sold 75,318 Amicus Therapeutics shares in Q2 2026, an estimated $1.09M.
  • PDT Partners first reported a position in Amicus Therapeutics in Q3 2014 and held it in 17 quarters.
  • PDT Partners's Amicus Therapeutics position peaked at $6.41M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.